Li Chunze, Subramanian Raju, Yu Sean, Prueksaritanont Thomayant
Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA.
Drug Metab Dispos. 2006 Jan;34(1):102-10. doi: 10.1124/dmd.105.006650. Epub 2005 Oct 26.
Formation of an acyl-CoA thioester has been proposed, but not directly demonstrated, to be a key step in mediating both lactonization and atypical beta-oxidation of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Here, we describe studies to characterize formation of acyl-CoA thioesters in vitro in mouse liver preparations using the hydroxy acid form of simvastatin (SVA) as a model substrate. With an optimized chromatography method, three new products were detected in addition to the dehydration product (P1) and the lactone form of simvastatin, which have been characterized previously (Prueksaritanont et al., 2001). Based on high-pressure liquid chromatography analysis, UV spectroscopy, mass spectrometry, and NMR spectral characterization, two metabolites were identified as acyl-CoA thioester conjugates of SVA and P1, respectively, whereas the third metabolite (M1) was confirmed to be the L-beta-hydroxy isomer of simvastatin. M1 was probably formed by stereospecific hydration, a previously reported reaction, and subsequent lactonization of P1-S-acyl CoA. Among all the mouse liver subcellular fractions, microsomes exhibited the highest capacity to catalyze the CoASH-dependent metabolism of SVA, whereas such activity was totally absent in cytosol. Together, these results provide direct experimental evidence that SVA (and conceivably other statins as well) is able to form an acyl-CoA thioester, possibly by microsomal long-chain acyl-CoA synthetase(s), leading to formation of two parallel metabolic pathways, one resulting in the two diastereomers of statin lactones (simvastatin and M1) and the other to the beta-oxidation pathway of statin hydroxy acids.
有人提出,酰基辅酶A硫酯的形成是介导3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂内酯化和非典型β-氧化的关键步骤,但尚未得到直接证实。在此,我们描述了以辛伐他汀(SVA)的羟酸形式作为模型底物,在小鼠肝脏制剂中体外表征酰基辅酶A硫酯形成的研究。通过优化的色谱方法,除了脱水产物(P1)和辛伐他汀的内酯形式(此前已对其进行了表征,Prueksaritanont等人,2001年)外,还检测到了三种新产物。基于高压液相色谱分析、紫外光谱、质谱和核磁共振光谱表征,两种代谢产物分别被鉴定为SVA和P1的酰基辅酶A硫酯共轭物,而第三种代谢产物(M1)被确认为辛伐他汀的L-β-羟基异构体。M1可能是通过立体特异性水合作用(一种先前报道的反应)以及随后P1-S-酰基辅酶A的内酯化形成的。在所有小鼠肝脏亚细胞组分中,微粒体表现出催化SVA的辅酶A依赖性代谢的最高能力,而胞质溶胶中则完全没有这种活性。总之,这些结果提供了直接的实验证据,表明SVA(可能其他他汀类药物也是如此)能够形成酰基辅酶A硫酯,可能是通过微粒体长链酰基辅酶A合成酶,从而导致形成两条平行的代谢途径,一条导致他汀内酯的两种非对映异构体(辛伐他汀和M1)的形成,另一条导致他汀羟酸的β-氧化途径。